title: The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
authors.affiliation: Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Hospital Duesseldorf, Germany. Electronic address: kuendgen@med.uni-duesseldorf.de.
authors.forename: Andrea
authors.initials: A
authors.lastname: Kuendgen
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D001803:Blood Transfusion; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D018450:Disease Progression; D006801:Humans; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D011379:Prognosis; D016019:Survival Analysis; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D013792:Thalidomide; D000077269:Lenalidomide
keywords: 5q− syndrome; Deletion 5q; Lenalidomide; Myelodysplastic syndrome; Prognostic markers; Transfusion dependency